Prostate cancer diagnostics has lived in a strange middle ground for years. MRI if you can get it. Blind biopsy if you cannot. Expensive machines in hospital basements. Guesswork in exam rooms. Then along comes a company called Exact Imaging and decides maybe “exact” should mean something.
Exact Imaging just secured a $10M financing led by iGan Partners, the firm that has backed the company since inception and remains its largest shareholder. That kind of loyalty in venture is not sentimental. It is conviction earned the hard way. Credit to Randy AuCoin, President & CEO, who has been building this story brick by brick since joining the predecessor business in 2011 and steering it into the Canadian entity we know today. And credit to Sam Ifergan, Founder of iGan Partners, whose early belief has compounded into leadership capital when it matters most.
The product is not theoretical. ExactVu is a 29 MHz micro-ultrasound platform that delivers real-time, high-resolution imaging of the prostate inside the urologist’s office. Not days later. Not in another building. During the biopsy. More than 300 customers worldwide are already using it. Over 100 peer-reviewed publications stand behind it. The OPTIMUM randomized controlled trial showed micro-ultrasound is non-inferior to MRI-fusion biopsy for detecting clinically significant cancer. Published in JAMA. Editor’s Choice. Presented as a Game Changer at EAU. And now recognized in the 2026 NCCN Guidelines for Early Detection. That is how you move from interesting device to clinical standard. Evidence first. Commercial execution second. Ego last.
This $10M round is fuel for global expansion. North America. Europe. Japan. South Korea. Taiwan. Brazil. Mexico. The map is already inked, and the installed base is growing on the back of record system sales in 2025. When you combine FDA 510(k) clearance, CE Mark approval, and a patent portfolio north of 100, you are not pitching potential. You are scaling momentum.
There is a bigger lesson here for founders. Exact Imaging did not chase noise. They built data. They ran trials. They earned guideline inclusion. They aligned with investors like iGan Partners who understand medtech timelines are marathons, not TikToks. When your cap table believes in the science as much as the spreadsheet, you buy yourself time to get it right.
For urologists, the value proposition is straightforward. High-resolution imaging in real time, in your office, integrated into your existing workflow. For health systems, it is access and efficiency. For patients, it is clarity when clarity counts.
